Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 1/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124121 | 0.85 | — | — | |
| SCHEMBL8737211 | 0.80 | LMNA (0.33) | — | |
| SCHEMBL29344707 | 0.78 | — | — | |
| SCHEMBL289063 | 0.76 | PARP15 (0.33) | PKLR | |
| SCHEMBL30829745 | 0.76 | PARP15 (0.33) | PKLR | |
| SCHEMBL8738103 | 0.73 | GPR55 (0.30) | — | |
| SCHEMBL23120378 | 0.72 | GRM4 (0.31) | — | |
| SCHEMBL24498806 | 0.72 | GRM4 (0.31) | — | |
| SCHEMBL29715196 | 0.72 | GRM4 (0.31) | — | |
| SCHEMBL25078994 | 0.72 | KDM4E (0.43) | PKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240025916-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY | 2024-01-25 | — | — | US | disclosed |
| US-20240025916-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY | 2024-01-25 | — | — | US | disclosed |
| WO-2023225252-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2022119748-A1 | TRICYCLIC KRAS G12C INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025916-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PKLR 3587/4885P4HB 3645/4885F2RL1 1246/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | PKLR 2968/4885P4HB 3680/4885F2RL1 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.